Cargando…
Pharmacogenomics and the Management of Mood Disorders—A Review
Due to the chronic relapsing nature of mental disorders and increased life expectancy, the societal burden of these non-communicable diseases will increase even further. Treatments for mental disorders, such as depression, are available, but their effect is limited due to patients’ (genetic) heterog...
Autores principales: | Kleine Schaars, Kristian, van Westrhenen, Roos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381396/ https://www.ncbi.nlm.nih.gov/pubmed/37511796 http://dx.doi.org/10.3390/jpm13071183 |
Ejemplares similares
-
Pharmacogenomics of Mood Stabilizers in the Treatment of Bipolar Disorder
por: Squassina, Alessio, et al.
Publicado: (2010) -
Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?
por: van Westrhenen, Roos, et al.
Publicado: (2020) -
Editorial: From Trial and Error to Individualised Pharmacogenomics-Based Pharmacotherapy in Psychiatry
por: van Westrhenen, R., et al.
Publicado: (2021) -
Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs
por: Le-Niculescu, H., et al.
Publicado: (2021) -
Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis
por: Steenen, Serge A, et al.
Publicado: (2016)